Denosumab has a greater preventive effect on fractures but an increased risk for MACE compared with oral bisphosphonates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback